RxDoctor Payments Data

Scott Kurzrok, DO

Family Medicine · Broomall, PANPI 1073515375

Payments from drug & device makers

$19,768in general payments, 2019–2025

Across 1,219 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$1K
  • GSK$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Bayer$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$19,62499%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)247$3,845
Novo Nordisk97$1,490
GSK97$1,404
Pfizer81$1,271
AstraZeneca63$1,217
Bayer63$1,156
Lilly USA, LLC74$1,118
Novartis45$648
Merck38$641
Amgen(2 entities)41$610
Astellas Pharma US Inc30$596
Boehringer Ingelheim30$540
Teva Pharmaceuticals USA, Inc.23$529
Kowa Pharmaceuticals America, Inc.65$515
Amarin Pharma, Inc.36$506
Almatica Pharma LLC15$271
Idorsia Pharmaceuticals US Inc11$259
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$254
Corium, LLC15$251
Otsuka America Pharmaceutical, Inc.13$225
Takeda Pharmaceuticals U.S.A., Inc.14$224
Abbott10$213
Sanofi-aventis U.S. LLC7$129
Johnson & Johnson5$127
Boston Scientific5$122
Exact Sciences5$108
Eisai Inc.6$106
Forte Bio-pharma LLC2$96
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$95
Biohaven Pharmaceuticals, Inc.5$82
Mylan Specialty L.p.4$82
Biodelivery Sciences International, Inc.5$76
Kvk-tech, Inc.1$73
Axsome Therapeutics, Inc.3$73
E.r. Squibb & Sons, L.L.C.3$69
Biohaven Pharmaceutical Holding Company Ltd.3$62
Vanda Pharmaceuticals Inc.2$60
Dexcom, Inc.2$59
Collegium Pharmaceutical, Inc.3$49
Arbor Pharmaceuticals, Inc.3$40
Shield Therapeutics Inc1$40
Scilex Pharmaceuticals Inc.2$35
Circassia Inc.2$33
Scpharmaceuticals Inc.1$32
Phathom Pharmaceuticals, Inc.2$28
Ferring Pharmaceuticals Inc.2$27
Stryker1$24
Sun Pharmaceutical Industries Inc.1$22
Lundbeck LLC1$22
Inari Medical, Inc.1$22
Hologic Sales And Service, LLC1$22
Aimmune Therapeutics, Inc.1$19
Ultragenyx Pharmaceutical Inc.1$18
Linus Health, Inc.1$17
Hikma Pharmaceuticals USA1$16
Otsuka Pharmaceutical Development & Commercialization, Inc.1$16
Inspire Medical Systems, Inc.1$16
Intra-sana Laboratories1$15
Philips North America LLC1$15
Vistapharm, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,768 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$410,050
Medicare patients
342
Services billed
4,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban363$154,185
JardianceEmpagliflozin116$67,197
CreonLipase/Protease/Amylase27$63,209
JanuviaSitagliptin Phosphate105$48,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$40,199
JanumetSitagliptin Phos/Metformin Hcl36$37,498
EntrestoSacubitril/Valsartan81$35,920
XareltoRivaroxaban76$32,162
FarxigaDapagliflozin Propanediol41$30,801
MounjaroTirzepatide13$25,186
OzempicSemaglutide21$23,039
MyrbetriqMirabegron67$19,608
TrulicityDulaglutide14$16,938
Janumet XrSitagliptin Phos/Metformin Hcl17$15,507
Atorvastatin Calcium891$12,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$1,271$164,609396 claims
MerckJanuvia, Janumet, Janumet Xr$641$101,571158 claims
Boehringer IngelheimJardiance, Tradjenta$540$74,798131 claims
AbbVieCreon$3,845$63,20927 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,404$52,17552 claims
Lilly USA, LLCMounjaro, Trulicity$1,118$42,12427 claims
AstraZenecaFarxiga, Lokelma$1,217$37,20893 claims
NovartisEntresto$648$35,92081 claims
Johnson & JohnsonXarelto$127$32,16276 claims
Novo NordiskOzempic$1,490$23,03921 claims
Astellas Pharma US IncMyrbetriq$596$19,60867 claims
BayerKerendia$1,156$12,05223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Broomall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →